CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...
CG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright ...
7h
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback